Author

G. Buene

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Sundan· 2 shared H. Hella· 2 shared K. Misund· 2 shared M. Westhrin· 2 shared M. Zahoor· 2 shared R. W. Groen· 2 shared S. H. Moen· 2 shared T. Holien· 2 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Sundan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

IL-32 is a metabolic regulator promoting survival and proliferation of malignant plasma cells

K. R. Aass, R. Mjelle, M. H. Kastnes, S. S. Tryggestad, L. M. van den Brink, M. Westhrin, M. Zahoor, S. H. Moen, G. Buene, K. Misund, A.-M. Sponaas, Q. Ma, A. Sundan, R. W. Groen, T. S. Slordahl, , T. Standal

This study shows IL-32 promotes survival and proliferation of malignant plasma cells by enhancing mitochondrial oxidative phosphorylation and altering metabolic pathways.

bioRxiv · Feb 22, 2021 · PreprintCancer Biology

Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on bone

M. Westhrin, T. Holien, M. Zahoor, S. H. Moen, G. Buene, B. Stordal, H. Hella, H. Yuan, J. D. de Bruijn, A. Martens, R. W. Groen, F. Bosch, U. Smith, A. M. Sponaas, A. Sundan, T. Standal

This study shows that BMP4 gene therapy reduces myeloma tumor growth in mice but also decreases trabecular bone volume.

bioRxiv · Mar 13, 2019Cancer Biology

BMPR2 inhibits activin- and BMP-signaling via wild type ALK2

O. E. Olsen, M. Sankar, S. Elsaadi, H. Hella, G. Buene, S. R. Darvekar, K. Misund, T. Katagiri, T. Holien

The paper shows that knocking down BMPR2 enhances SMAD1/5/8 activation by activin A, activin B, and certain BMPs through wild type ALK2 in multiple myeloma cells.

bioRxiv · Nov 22, 2017Cell Biology